ReviewNature reviews. Genetics2010
Genome-wide association studies in pharmacogenomics.
Review in Nature reviews. Genetics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Associations between genetic polymorphisms of membrane transporter genes and prognosis after chemotherapy: meta-analysis and finding from Seoul Breast Cancer Study (SEBCS).The pharmacogenomics journal · 2018Pooled it
- Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval.The pharmacogenomics journal · 2014Pooled it
- Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis.Annals of the rheumatic diseases · 2011Pooled it
- PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.Pharmacotherapy · 2014Trial
- Genome-wide association study identifies a potent locus associated with human opioid sensitivity.Molecular psychiatry · 2014Trial
- Candidate gene studies of a promising intermediate phenotype: failure to replicate.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Trial
- Trial
- A Human Pharmacogenomics Approach Provides Insight Into the Pathogenesis and Pathophysiology of Steroid-Induced Ocular Hypertension.Ophthalmology science · 2026Article
- Polygenic risk scores in pharmacogenomics: methodological challenges, current applications, and perspectives for clinical implementation.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2026Article
- Review
- Potential signaling pathways, biomarkers, natural drugs, and chronic myeloid leukemia therapeutics.Frontiers in pharmacology · 2025Review
- From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Identification of drug responsive enhancers by predicting chromatin accessibility change from perturbed gene expression profiles.NPJ systems biology and applications · 2024Article
- Cytochrome P450 Transcriptional Regulation by Testis-Specific Y-Encoded-Like Protein: Identification of Novel Upstream Transcription Factors.Drug metabolism and disposition: the biological fate of chemicals · 2023Article
- Article
- A Systematic Review of Polygenic Models for Predicting Drug Outcomes.Journal of personalized medicine · 2022Review
- Genome-Wide Studies in Ischaemic Stroke: Are Genetics Only Useful for Finding Genes?International journal of molecular sciences · 2022Review
- Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study.Translational psychiatry · 2022Article
- From pharmacogenetics to pharmaco-omics: Milestones and future directions.HGG advances · 2022Review
- Associations between thePharmaceutics · 2022Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genome-wide association (GWA) studies for pharmacogenomics-related traits are increasingly being performed to identify loci that affect either drug response or susceptibility to adverse drug reactions. Until now, only the largest effects have been detected, partly because of the challenges of obtaining large numbers of cases for pharmacogenomic studies. Since 2007, a range of pharmacogenomics GWA studies have been published that have identified several interesting and novel associations between drug responses or reactions and clinically relevant loci, showing the value of this approach.
Indexed as
Identifiers
20300088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.